Lexeo Therapeutics (LXEO) Equity Average (2022 - 2026)

Lexeo Therapeutics' Equity Average history runs 5 years deep, the most recent figure standing at $239.1 million for Q1 2026.

• In Q1 2026, Equity Average rose 133.3% year-over-year to $239.1 million; the TTM figure through Mar 2026 stood at $239.1 million (up 133.3% YoY), while the FY2025 annual figure was $181.8 million, up 57.79% from the prior year.
• Equity Average came in at $239.1 million for Q1 2026 at Lexeo Therapeutics, up from $183.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $239.1 million in Q1 2026 to a low of -$153.2 million in Q3 2023.
• A 5-year average of $59.1 million and a median of $120.6 million in 2024 frame the typical range for Equity Average.
• Across the five-year window, Equity Average soared 619.9% in 2024 and tumbled 34.94% in 2025, its largest moves.
• Lexeo Therapeutics' Equity Average stood at -$106.0 million in 2022, then soared by 76.75% to -$24.6 million in 2023, then jumped by 619.9% to $128.1 million in 2024, then jumped by 43.46% to $183.8 million in 2025, then surged by 30.11% to $239.1 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $239.1 million, $183.8 million, and $129.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison